Jäger Christina, Dimitrova Polina, Sun Qiong, Tennebroek Jesse, Marchiori Elisa, Jaritz Markus, Rauschmeier Rene, Estivill Guillem, Obenauf Anna, Busslinger Meinrad, van der Veeken Joris
Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Campus-Vienna-Biocenter 1, A-1030 Vienna, Austria.
Vienna BioCenter PhD Program, Doctoral School of the University of Vienna and Medical University of Vienna, 1030 Vienna, Austria.
Sci Immunol. 2025 Jun 6;10(108):eadr7057. doi: 10.1126/sciimmunol.adr7057.
Regulatory T cells (T cells) are immunosuppressive CD4 T cells defined by expression of the transcription factor Foxp3. Genetic loss-of-function mutations in cause lethal multiorgan autoimmune inflammation resulting from defects in T cell development and suppressive activity. Whether T cells are continuously dependent on Foxp3 is still unclear. Here, we leveraged chemically induced protein degradation to show that functionally suppressive T cells in healthy organs can persist in the near-complete absence of Foxp3 protein for at least 10 days. Conversely, T cells responding to type 1 inflammation in settings of autoimmunity, viral infection, or cancer were selectively lost upon Foxp3 protein depletion. Acute degradation experiments revealed that Foxp3 acts mostly as a direct transcriptional repressor and modulates responsiveness to cytokine stimulation. This inflammation-dependent requirement for continuous Foxp3 activity enabled induction of a selective antitumor immune response upon systemic Foxp3 depletion, without causing deleterious T cell expansion in healthy organs.
调节性T细胞(Tregs)是一类免疫抑制性CD4 T细胞,由转录因子Foxp3的表达所定义。Foxp3基因功能丧失性突变会导致T细胞发育和抑制活性缺陷,从而引发致死性多器官自身免疫性炎症。Tregs是否持续依赖Foxp3仍不清楚。在此,我们利用化学诱导的蛋白质降解来表明,健康器官中具有功能抑制作用的Tregs在几乎完全缺乏Foxp3蛋白的情况下仍可存活至少10天。相反,在自身免疫、病毒感染或癌症背景下对1型炎症作出反应的Tregs在Foxp3蛋白耗竭后会选择性丢失。急性降解实验表明,Foxp3主要作为直接转录抑制因子发挥作用,并调节对细胞因子刺激的反应性。这种炎症依赖性对持续Foxp3活性的需求使得在全身Foxp3耗竭后能够诱导选择性抗肿瘤免疫反应,而不会在健康器官中引起有害的T细胞扩增。
J Allergy Clin Immunol. 2017-2
Sci Transl Med. 2024-10-16
Expert Rev Clin Immunol. 2016
Curr Opin Immunol. 2024-8
J Exp Med. 2024-9-2
Nat Rev Immunol. 2023-12
Nat Immunol. 2023-5